EW vs GEHC
Edwards Lifesciences and GE HealthCare, both Healthcare
Edwards Lifesciences is the larger company at $50B against $28B. On trailing earnings GEHC is the cheaper of the two at a P/E of 17.5 against 52.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +15% against +4.9% for GEHC. Ryufin's sector-relative Smart Score puts GEHC ahead, 9/10 against 7/10.
| Figure | EW | GEHC |
|---|---|---|
| Last close | $90.77 | $73.31 |
| Market cap | $50B | $28B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 52.2 | 17.5 |
| Dividend yield | n/a | 0.2% |
| 1-year return | +15% | +4.9% |
| 5-year return | -19% | n/a |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 73% of the disclosed total.
GE HealthCare
Revenue of $5.1B in Q1 2026, net income $389M. Its largest reported line is AIS, 64% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.